1. The signing of a major commercial agreement with the German company Ursatec, marking a new milestone in the development of our nasal line.
2. The confirmed support of public investors, notably Noshaq and O.B.I./Move Invest, who reaffirm their confidence in Aquilon Pharma’s growth potential.
3. The confirmation of the commitment of our long-standing investors, who continue to actively support our long-term strategy.
4. The renewed support of our banking partners, demonstrating the strength of the project and the credibility of our vision.

Thanks to this fundraising, the launch of the first medical device developed in partnership with Ursatec is fully confirmed for the end of 2025, in line with the established schedule.

Aquilon Pharma would like to thank all its partners for their trust and commitment to this new phase of development.

L’article Aquilon Pharma secures €6 million in refinancing to support the commercial launch of its nasal product line est apparu en premier sur Aquilon Pharma.

This unique and patented formulation technology achieves 79% deposition of the fine particle fraction and 70% deposition of the expired fraction using a standard inhaler device, representing a breakthrough in inhalation therapy.

These key data represent an important step forward in confirming Aquilon Pharma’s potential in the development of formulations for dry powder inhalers.

As a result, Aquilon can now move forward with great confidence with dry powder formulations of novel and biologic treatments to be delivered by inhalation.

L’article Aquilon proves the high potential of HP-Betadex in Dry Powder formulation est apparu en premier sur Aquilon Pharma.

The panel of international experts sitting on the jury notes that “the project remains very interesting and has strong industrial potential”.

L’article Aquilon and partners cross the mid-term milestone for Aeronext est apparu en premier sur Aquilon Pharma.

Aquilon Pharmaceuticals immediately kicked off the project to add International Expertise and Experience to its different Governance layers, and started the implementation, following unanimous acceptance of the plan by the Board on December 7th.

In a first phase of this exercise, the Board of Directors approved the nomination of Dr Hassan Benameur as Board Member, replacing Mr Patrick Jeanmart who decided to step down to focus on other activities.

Dr Hassan Benameur has a PhD in Pharmaceutical and Drug Design and is Chemical Engineer Chemistry and Biochemistry. He previously held executive positions at Lonza, Pfizer and Capsugel and is Adjunct Professor at Monash University. In addition to his role at the Board, Dr Benameur will assist the executive team in Scientific Affairs and Business Development.

Aquilon Pharmaceuticals wishes to thank Patrick Jeanmart and warmly welcome Dr Hassan Benameur.

With these moves, the first phase of the Board reshuffle is completed. A second phase, including new nominations, will be announced by the end of January 2023.

L’article Board reshuffle at Aquilon Pharmaceuticals est apparu en premier sur Aquilon Pharma.